{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:37:37Z","timestamp":1784039857522,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,2,10]],"date-time":"2010-02-10T00:00:00Z","timestamp":1265760000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s00520-009-0744-x","type":"journal-article","created":{"date-parts":[[2010,2,9]],"date-time":"2010-02-09T09:41:25Z","timestamp":1265708485000},"page":"509-522","source":"Crossref","is-referenced-by-count":114,"title":["A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group"],"prefix":"10.1007","volume":"18","author":[{"given":"Mario E.","family":"Lacouture","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Segaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Setser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy P.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel B.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Barasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis P.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo L.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Kris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Basch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Eaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Kurtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise A.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Dancey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Trotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,10]]},"reference":[{"key":"744_CR1","unstructured":"CTC v2.0 and common terminology criteria for adverse events v3.0 (CTCAE). Available at http:\/\/ctep.cancer.gov\/reporting\/index.html . Accessed on 4 Mar 2008. CTCAE v4.0 available on May 28, 2009 at https:\/\/cabig-kc.nci.nih.gov\/Vocab\/KC\/index.php\/CTCAE"},{"issue":"4","key":"744_CR2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jnci\/djm324","volume":"100","author":"M Edgerly","year":"2008","unstructured":"Edgerly M, Fojo T (2008) Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst 100(4):240\u2013242","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"744_CR3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2006.04.062","volume":"55","author":"E Ro\u00e9","year":"2006","unstructured":"Ro\u00e9 E, Garc\u00eda Muret MP, Marcuello E, Capdevila J, Pallar\u00e9s C, Alomar A (2006) Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 55(3):429\u2013437","journal-title":"J Am Acad Dermatol"},{"key":"744_CR4","first-page":"34","volume":"21","author":"LI Wagner","year":"2007","unstructured":"Wagner LI, Lacouture ME (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist\u2019s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology 21:34\u201336","journal-title":"Oncology"},{"issue":"3\u20134","key":"744_CR5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","volume":"72","author":"SL Boone","year":"2007","unstructured":"Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72(3\u20134):152\u2013159","journal-title":"Oncology"},{"key":"744_CR6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341\u2013354","journal-title":"Nat Rev Cancer"},{"key":"744_CR7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrd1066","volume":"2","author":"J Dancey","year":"2003","unstructured":"Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2:296\u2013313","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"744_CR8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6(10):803\u201312","journal-title":"Nat Rev Cancer"},{"key":"744_CR9","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","volume":"23","author":"R Perez-Soler","year":"2005","unstructured":"Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23:5235\u20135246","journal-title":"J Clin Oncol"},{"issue":"9","key":"744_CR10","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","volume":"16","author":"S Segaert","year":"2005","unstructured":"Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16(9):1425\u20131433","journal-title":"Ann Oncol"},{"key":"744_CR11","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA) term and code. Available at http:\/\/www.meddramsso.org"},{"issue":"32","key":"744_CR12","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","volume":"25","author":"A Trotti","year":"2007","unstructured":"Trotti A, Colevas AD, Setser A, Basch E (2007) Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25(32):5121\u20135127","journal-title":"J Clin Oncol"},{"issue":"32","key":"744_CR13","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1200\/JCO.2007.11.3324","volume":"25","author":"DW Bruner","year":"2007","unstructured":"Bruner DW, Bryan CJ, Aaronson N, Blackmore CC, Brundage M, Cella D, National Cancer Institute et al (2007) Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute\u2014sponsored clinical trials networks. J Clin Oncol 25(32):5051\u20135057","journal-title":"J Clin Oncol"},{"issue":"32","key":"744_CR14","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1200\/JCO.2007.12.7670","volume":"25","author":"JA Sloan","year":"2007","unstructured":"Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G, National Cancer Institute et al (2007) Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute\u2014sponsored clinical trials networks. J Clin Oncol 25(32):5070\u20135077","journal-title":"J Clin Oncol"},{"issue":"6","key":"744_CR15","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","volume":"144","author":"KJ Busam","year":"2001","unstructured":"Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144(6):1169\u20131176","journal-title":"Br J Dermatol"},{"issue":"3","key":"744_CR16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2006.09.013","volume":"56","author":"LP Fox","year":"2007","unstructured":"Fox LP (2007) Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 56(3):460\u2013465 Epub 2006 Dec 4","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"744_CR17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1046\/j.1365-2133.2003.05725.x","volume":"150","author":"RL Baran","year":"2004","unstructured":"Baran RL (2004) A nail psoriasis severity index. Br J Dermatol 150(3):568\u2013569","journal-title":"Br J Dermatol"},{"issue":"5","key":"744_CR18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3816\/CCC.2008.n.040","volume":"7","author":"KA Bauer","year":"2008","unstructured":"Bauer KA, Hammerman S, Rapoport B, Lacouture ME (2008) Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in Phase II and III colorectal cancer clinical trials. Clin Colorectal Cancer 7(5):309\u2013314","journal-title":"Clin Colorectal Cancer"},{"key":"744_CR19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D et al (2004) Alopecia areata investigational assessment guidelines, Part II. J Am Acad Dermatol 51:440\u2013447","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"744_CR20","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/cncr.24120","volume":"115","author":"A Tejwani","year":"2009","unstructured":"Tejwani A, Wu S, Jia Y, Agulnik\u03b3 M, Millender L, Lacouture ME (2009) Increased risk of high-grade dermatologic toxicities with combined radiation plus EGFR inhibitor therapy. Cancer 115(6):1286\u20131299","journal-title":"Cancer"},{"issue":"26","key":"744_CR21","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2007.13.3983","volume":"25","author":"SM Bentzen","year":"2007","unstructured":"Bentzen SM, Trotti A (2007) Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 25(26):4096\u20134103","journal-title":"J Clin Oncol"},{"key":"744_CR22","unstructured":"Tykerb Package Insert (2007) Glaxo Smith Kline (Research Triangle Park, NC). http:\/\/us.gsk.com\/products\/assets\/us_tykerb.pdf . Accessed 11 July 2007"},{"issue":"4 Suppl 1","key":"744_CR23","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/01.NCC.0000281759.23823.82","volume":"30","author":"S Basti","year":"2007","unstructured":"Basti S (2007) Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs 30(4 Suppl 1):S10\u2013S16","journal-title":"Cancer Nurs"},{"issue":"4","key":"744_CR24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337\u2013345","journal-title":"N Engl J Med"},{"key":"744_CR25","unstructured":"Erbitux Package Insert. (2006) ImClone Systems Incorporated and Bristol-Myers Squibb Company (Branchburg and Princeton, NJ). http:\/\/erbitux.com\/erb\/pdf\/PI.pdf . Accessed 24 May 2007"},{"key":"744_CR26","unstructured":"Vectibix Package Insert. Amgen, Inc. Thousand Oaks, CA. U.S. Food and Drug Administration website. http:\/\/www.fda.gov\/cder\/foi\/label\/2006\/125147s0000lbl.pdf . Accessed 14 May 2007"},{"issue":"2","key":"744_CR27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123\u2013132","journal-title":"N Engl J Med"},{"key":"744_CR28","unstructured":"Tarceva Package Insert (2005) OSI Pharmaceuticals, Inc. (Melville, NY). http:\/\/www.gene.com\/gene\/products\/information\/pdf\/tarceva-prescribing.pdf . Accessed 24 May 2007"},{"issue":"26","key":"744_CR29","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733\u20132743","journal-title":"N Engl J Med"},{"key":"744_CR30","unstructured":"Lapatinib Package Insert (2007) Glaxo Smith Cline (Research Triangle Park, NC). http:\/\/www.tykerb.com\/hcp\/index.htm"},{"issue":"13","key":"744_CR31","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25(13):1658\u20131664","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0744-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-009-0744-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0744-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:01:55Z","timestamp":1559080915000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-009-0744-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,10]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1007\/s00520-009-0744-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,10]]}}}